Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain

5Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The presence of intact ligand-binding domain (LBD) ensures the strict androgen-dependent regulation of androgen receptor (AR): binding of androgen induces structural reorganization of LBD resulting in release of AR from HSP90, suppression of nuclear export which otherwise dominates over import and nuclear translocation of AR as a transcription factor. Thus, loss or defects of the LBD abolish constraint from un-liganded LBD as exemplified by constitutively active AR variants (AR-Vs), which are associated with emerging resistance mechanism to anti-AR therapy in castration-resistant prostate cancer (mCRPC). Recent analysis of the AR splicing landscapes revealed mCRPC harboring multiple AR-Vs with diverse patterns of inclusion/exclusion of exons (exons 4-8) corresponding to LBD to produce namely exon-skipping variants. In silico construction for these AR-Vs revealed four novel AR-Vs having unique features: Exclusion of specified exons introduces a frameshift in variants v5es, v6es and v7es. ARv56es maintains the reading frame resulting in the inclusion of the C-terminal half of the LBD. We systematically characterized these AR-Vs regarding their subcellular localization, affinity for HSP90 and transactivation capability. Notably, ARv5es was free from HSP90, exclusively nuclear, and constitutively active similarly as previously reported for v567es. In contrast, v6es and v7es were similar in that they are cytoplasmic, transcriptionally inactive and bind HSP90, ARv56es was present in both nucleus and cytoplasm, does not bind HSP90 and is transcriptionally inactive. Converting these transcriptionally inactive AR-Vs into active forms, we identified the two separate elements that allosterically suppress otherwise constitutively active AR-Vs; one in exon 5 for v6es and v7es and the other in exon 8 for v56es. Our findings identify a novel constitutively active AR-V, ARv5es and establish a method to predict potential activities of AR-Vs carrying impaired LBD.

References Powered by Scopus

Increased survival with enzalutamide in prostate cancer after chemotherapy

3900Citations
N/AReaders
Get full text

Abiraterone and increased survival in metastatic prostate cancer

3798Citations
N/AReaders
Get full text

Improved vectors and genome-wide libraries for CRISPR screening

3596Citations
N/AReaders
Get full text

Cited by Powered by Scopus

DNA Damage Repair Deficiency in Prostate Cancer

36Citations
N/AReaders
Get full text

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer

27Citations
N/AReaders
Get full text

A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells

26Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Uo, T., Dvinge, H., Sprenger, C. C., Bradley, R. K., Nelson, P. S., & Plymate, S. R. (2017). Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Oncogene, 36(10), 1440–1450. https://doi.org/10.1038/onc.2016.313

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

57%

Researcher 9

30%

Professor / Associate Prof. 3

10%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 16

52%

Medicine and Dentistry 7

23%

Agricultural and Biological Sciences 6

19%

Pharmacology, Toxicology and Pharmaceut... 2

6%

Save time finding and organizing research with Mendeley

Sign up for free